Clinical Trial

NG2 and DLL3 CAR-T Cells Targeting Melanoma

Name: NG2 and DLL3 CAR-T Cells Targeting Melanoma — clinical trial record (NCT07193966)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Recruiting Phase 1/2

View on ClinicalTrials.gov →

Summary

The purpose of this study is to assess the feasibility, safety and efficacy of multiple CAR-T cell therapy which targets NG2 and DLL3 surface antigens in patients with relapsed and refractory melanoma.

Trial Details

NCT Number	NCT07193966
Lead Sponsor	Shenzhen Geno-Immune Medical Institute
Conditions	Melanoma
Enrollment	100 participants
Start Date	2025-09-01
Primary Completion	2028-12-31 (estimated)
Study Completion	2029-12-31 (estimated)
Updated on ClinicalTrials.gov	2025-09-26